Tectonic Advisors 13F: Adds $852K to HealthEquity (HQY) Stake

Tectonic Advisors grew its stake in HealthEquity, Inc. HQY by 9.6% during the period, purchasing an additional 9,630 shares to bring its total investment to 109,953 shares. According to a Form 13F filing on October 22, 2026, the updated position was valued at approximately $9,726,418. The stock closed at $100.97 on the day the filing was made public.

HQY HealthEquity, Inc.

$99.79 ▲ +9.58% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in Tectonic Advisors's HealthEquity Position

The fund added 9,630 shares to its portfolio, lifting its holdings from 100,953 prior shares up to 109,953 shares total. This 9.6% boost expanded the dollar value of the position to nearly $9.73 million based on period values.

Other Institutional Activity in HealthEquity

Other large institutional investors adjusted their positions in the health services firm during recent periods. Wasatch Advisors LP cut its holdings by 948,873 shares, ending with 7,011,469 shares worth about $707,948,033. AQR Capital Management, LLC trimmed its stake by 93,108 shares to hold 1,999,209 shares valued at about $201,860,135. William Blair Investment Management, LLC grew its holdings by 113,679 shares, ending with 1,773,227 shares worth about $179,042,732.

HealthEquity, Inc. Stock Up 1.7%

HealthEquity shares recently traded around $99.59 as of October 23, 2026, down about 1.4% from the filing date close of $100.97. The stock sits 4.2% above its 50-day moving average of $95.57 and 12.3% above its 200-day moving average of $88.67. The share price rests 7.5% below its 52-week high of $107.62 and 36.9% above its 52-week low of $72.76, while trading 17.5% below the average analyst price target.

Recent Earnings

HealthEquity reported trailing twelve month revenue of $1.36 billion alongside earnings of $2.77 per share. The company posted a net profit margin of 17.4% and a return on equity of 11.4%, with its next earnings report scheduled for December 2, 2026.

Insider Buying and Selling at HealthEquity, Inc.

Company insiders completed several transactions prior to the filing, including officer and director sales along with an open-market purchase by officer Sunil Rajasekar of 131 shares on October 15, 2026.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock recently, including BMO Capital maintaining its outperform rating on October 21, 2026, while raising its price target to $125. The company carries a strong buy recommendation consensus among 15 analysts with an average target price of $120.67.

About HealthEquity

HealthEquity, Inc. builds technology platforms that help consumers and employers manage health savings accounts and investment options. Headquartered in Draper, Utah, the firm provides digital financial tools designed to help individuals save and invest for healthcare expenses.

Bottom Line

Institutional adjustments in HealthEquity highlight active portfolio balancing ahead of the company's upcoming earnings release on December 2, 2026. Investors will closely watch whether upcoming financial results align with the strong buy consensus and positive analyst expectations currently surrounding the healthcare platform.